surmount-1 tirzepatide trial obesity without diabetes for Obesity: Highlights from the Gastrointestinal tolerability and weight reduction

Weight regain after stopping is common

The reduction in the BMI for those receiving tirzepatide and other incretin-based therapies is substantial but is not instantaneous

Consent can always be revoked via the unsubscribe link in newsletters.BackSubscribe

Shima Hadidchi to discuss your eligibility for Tirzepatide

real-world clinical experience suggests they may provide meaningful weight loss and health benefits

Semaglutide: GLP-1 receptor agonist Mimics the bodys natural GLP-1 hormone to regulate hunger and insulin Slows gastric emptying and increases satiety Marketed under brand names like Ozempic and Wegovy Learn more about how our team delivers care with semaglutide by visiting our Semaglutide weight management page